Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study

Santema, B. T.; Ouwerkerk, W.; Tromp, J.; Sama, I. E.; Ravera, A.; Regitz-Zagrosek, V.; Hillege, H.; Samani, N. J.; Zannad, F.; Dickstein, K.; Lang, C. C.; Cleland, J. G.; Ter Maaten, J. M.; Metra, M.; Anker, S. D.; Van Der Harst, P.; L. L., Ng; Van Der Meer, P.; Van Veldhuisen, D. J.; Meyer, S.; Lam, C. S. P.; Richards, A. M.; Lam, C. S. P.; Anand, I.; Hung, C. -L.; Ling, L. H.; Liew, H. B.; Narasimhan, C.; Ngarmukos, T.; Park, S. W.; Reyes, E.; Siswanto, B. B.; Shimizu, W.; Zhang, S.; Voors, A. A.

doi:10.1016/S0140-6736(19)31792-1

Guideline-recommended doses of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), and β blockers are similar for men and women with heart failure with reduced ejection fraction (HFrEF), even though there are known sex differences in pharmacokinetics of these drugs. We hypothesised that there might be sex differences in the optimal dose of ACE inhibitors or ARBs and β blockers in patients with HFrEF.

Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study / Santema, B. T.; Ouwerkerk, W.; Tromp, J.; Sama, I. E.; Ravera, A.; Regitz-Zagrosek, V.; Hillege, H.; Samani, N. J.; Zannad, F.; Dickstein, K.; Lang, C. C.; Cleland, J. G.; Ter Maaten, J. M.; Metra, M.; Anker, S. D.; Van Der Harst, P.; Ng, L. L.; Van Der Meer, P.; Van Veldhuisen, D. J.; Meyer, S.; Lam, C. S. P.; Richards, A. M.; Lam, C. S. P.; Anand, I.; Hung, C. -L.; Ling, L. H.; Liew, H. B.; Narasimhan, C.; Ngarmukos, T.; Park, S. W.; Reyes, E.; Siswanto, B. B.; Shimizu, W.; Zhang, S.; Voors, A. A.. - In: THE LANCET. - ISSN 0140-6736. - 394:10205(2019), pp. 1254-1263. [10.1016/S0140-6736(19)31792-1]